Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)

Kyung Jin Kim, Sang Hyun Kim, Young Won Yoon, Seung-Woon Rha, Soon Jun Hong, Choong Hwan Kwak, Weon Kim, Chang Wook Nam, Moo Yong Rhee, Tae Ho Park, Taek Jong Hong, Sungha Park, Youngkeun Ahn, Namho Lee, Hui Kyung Jeon, Dong Woon Jeon, Kyoo Rok Han, Keon Woong Moon, In Ho Chae, Hyo soo Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aim: We aimed to compare the effects of fixed-dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a subgroup analysis of patients with diabetes mellitus (DM) or metabolic syndrome (MetS). Method: This multicenter eight-week randomized double-blind phase III study evaluated the safety and efficacy of fixed-dose combinations of ezetimibe 10 mg plus rosuvastatin, compared with rosuvastatin alone in patients with primary hypercholesterolemia. Four hundred and seven patients with primary hypercholesterolemia who required lipid-lowering treatment according to the ATP III guideline were randomized to one of the following six treatments for 8 weeks: fixed-dose combinations with ezetimibe 10 mg daily plus rosuvastatin (5, 10, or 20 mg daily) or rosuvastatin alone (5, 10, or 20 mg daily). Results: Fixed-dose combination of ezetimibe plus rosuvastatin significantly reduced LDL cholesterol, total cholesterol, and triglyceride levels compared with rosuvastatin alone. Depending on the rosuvastatin dose, these fixed-dose combinations of ezetimibe plus rosuvastatin provided LDL cholesterol, total cholesterol, and triglyceride reductions of 56%–63%, 37%–43%, and 19%–24%, respectively. Moreover, the effect of combination treatment on cholesterol levels was more pronounced in patients with DM or MetS than in non-DM or non-MetS patients, respectively, whereas the effect of rosuvastatin alone did not differ between DM vs non-DM or MetS vs non-MetS patients. Conclusion: Fixed-dose combinations of ezetimibe and rosuvastatin provided significantly superior efficacy to rosuvastatin alone in lowering LDL cholesterol, total cholesterol, and triglyceride levels. Moreover, the reduction rate was greater in patients with DM or MetS.

Original languageEnglish
Pages (from-to)371-382
Number of pages12
JournalCardiovascular Therapeutics
Volume34
Issue number5
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Hypercholesterolemia
Multicenter Studies
Diabetes Mellitus
Cholesterol
LDL Cholesterol
Triglycerides
Ezetimibe
Rosuvastatin Calcium
Therapeutics
Adenosine Triphosphate
Guidelines

Keywords

  • Cholesterol
  • Diabetes mellitus
  • Ezetimibe
  • Hypercholesterolemia
  • Metabolic syndrome
  • Rosuvastatin

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia : MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). / Kim, Kyung Jin; Kim, Sang Hyun; Yoon, Young Won; Rha, Seung-Woon; Hong, Soon Jun; Kwak, Choong Hwan; Kim, Weon; Nam, Chang Wook; Rhee, Moo Yong; Park, Tae Ho; Hong, Taek Jong; Park, Sungha; Ahn, Youngkeun; Lee, Namho; Jeon, Hui Kyung; Jeon, Dong Woon; Han, Kyoo Rok; Moon, Keon Woong; Chae, In Ho; Kim, Hyo soo.

In: Cardiovascular Therapeutics, Vol. 34, No. 5, 01.10.2016, p. 371-382.

Research output: Contribution to journalArticle

Kim, KJ, Kim, SH, Yoon, YW, Rha, S-W, Hong, SJ, Kwak, CH, Kim, W, Nam, CW, Rhee, MY, Park, TH, Hong, TJ, Park, S, Ahn, Y, Lee, N, Jeon, HK, Jeon, DW, Han, KR, Moon, KW, Chae, IH & Kim, HS 2016, 'Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)', Cardiovascular Therapeutics, vol. 34, no. 5, pp. 371-382. https://doi.org/10.1111/1755-5922.12213
Kim, Kyung Jin ; Kim, Sang Hyun ; Yoon, Young Won ; Rha, Seung-Woon ; Hong, Soon Jun ; Kwak, Choong Hwan ; Kim, Weon ; Nam, Chang Wook ; Rhee, Moo Yong ; Park, Tae Ho ; Hong, Taek Jong ; Park, Sungha ; Ahn, Youngkeun ; Lee, Namho ; Jeon, Hui Kyung ; Jeon, Dong Woon ; Han, Kyoo Rok ; Moon, Keon Woong ; Chae, In Ho ; Kim, Hyo soo. / Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia : MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). In: Cardiovascular Therapeutics. 2016 ; Vol. 34, No. 5. pp. 371-382.
@article{6b42abf5f23e4268ba88be7bec0129e6,
title = "Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)",
abstract = "Aim: We aimed to compare the effects of fixed-dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a subgroup analysis of patients with diabetes mellitus (DM) or metabolic syndrome (MetS). Method: This multicenter eight-week randomized double-blind phase III study evaluated the safety and efficacy of fixed-dose combinations of ezetimibe 10 mg plus rosuvastatin, compared with rosuvastatin alone in patients with primary hypercholesterolemia. Four hundred and seven patients with primary hypercholesterolemia who required lipid-lowering treatment according to the ATP III guideline were randomized to one of the following six treatments for 8 weeks: fixed-dose combinations with ezetimibe 10 mg daily plus rosuvastatin (5, 10, or 20 mg daily) or rosuvastatin alone (5, 10, or 20 mg daily). Results: Fixed-dose combination of ezetimibe plus rosuvastatin significantly reduced LDL cholesterol, total cholesterol, and triglyceride levels compared with rosuvastatin alone. Depending on the rosuvastatin dose, these fixed-dose combinations of ezetimibe plus rosuvastatin provided LDL cholesterol, total cholesterol, and triglyceride reductions of 56{\%}–63{\%}, 37{\%}–43{\%}, and 19{\%}–24{\%}, respectively. Moreover, the effect of combination treatment on cholesterol levels was more pronounced in patients with DM or MetS than in non-DM or non-MetS patients, respectively, whereas the effect of rosuvastatin alone did not differ between DM vs non-DM or MetS vs non-MetS patients. Conclusion: Fixed-dose combinations of ezetimibe and rosuvastatin provided significantly superior efficacy to rosuvastatin alone in lowering LDL cholesterol, total cholesterol, and triglyceride levels. Moreover, the reduction rate was greater in patients with DM or MetS.",
keywords = "Cholesterol, Diabetes mellitus, Ezetimibe, Hypercholesterolemia, Metabolic syndrome, Rosuvastatin",
author = "Kim, {Kyung Jin} and Kim, {Sang Hyun} and Yoon, {Young Won} and Seung-Woon Rha and Hong, {Soon Jun} and Kwak, {Choong Hwan} and Weon Kim and Nam, {Chang Wook} and Rhee, {Moo Yong} and Park, {Tae Ho} and Hong, {Taek Jong} and Sungha Park and Youngkeun Ahn and Namho Lee and Jeon, {Hui Kyung} and Jeon, {Dong Woon} and Han, {Kyoo Rok} and Moon, {Keon Woong} and Chae, {In Ho} and Kim, {Hyo soo}",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/1755-5922.12213",
language = "English",
volume = "34",
pages = "371--382",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia

T2 - MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)

AU - Kim, Kyung Jin

AU - Kim, Sang Hyun

AU - Yoon, Young Won

AU - Rha, Seung-Woon

AU - Hong, Soon Jun

AU - Kwak, Choong Hwan

AU - Kim, Weon

AU - Nam, Chang Wook

AU - Rhee, Moo Yong

AU - Park, Tae Ho

AU - Hong, Taek Jong

AU - Park, Sungha

AU - Ahn, Youngkeun

AU - Lee, Namho

AU - Jeon, Hui Kyung

AU - Jeon, Dong Woon

AU - Han, Kyoo Rok

AU - Moon, Keon Woong

AU - Chae, In Ho

AU - Kim, Hyo soo

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Aim: We aimed to compare the effects of fixed-dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a subgroup analysis of patients with diabetes mellitus (DM) or metabolic syndrome (MetS). Method: This multicenter eight-week randomized double-blind phase III study evaluated the safety and efficacy of fixed-dose combinations of ezetimibe 10 mg plus rosuvastatin, compared with rosuvastatin alone in patients with primary hypercholesterolemia. Four hundred and seven patients with primary hypercholesterolemia who required lipid-lowering treatment according to the ATP III guideline were randomized to one of the following six treatments for 8 weeks: fixed-dose combinations with ezetimibe 10 mg daily plus rosuvastatin (5, 10, or 20 mg daily) or rosuvastatin alone (5, 10, or 20 mg daily). Results: Fixed-dose combination of ezetimibe plus rosuvastatin significantly reduced LDL cholesterol, total cholesterol, and triglyceride levels compared with rosuvastatin alone. Depending on the rosuvastatin dose, these fixed-dose combinations of ezetimibe plus rosuvastatin provided LDL cholesterol, total cholesterol, and triglyceride reductions of 56%–63%, 37%–43%, and 19%–24%, respectively. Moreover, the effect of combination treatment on cholesterol levels was more pronounced in patients with DM or MetS than in non-DM or non-MetS patients, respectively, whereas the effect of rosuvastatin alone did not differ between DM vs non-DM or MetS vs non-MetS patients. Conclusion: Fixed-dose combinations of ezetimibe and rosuvastatin provided significantly superior efficacy to rosuvastatin alone in lowering LDL cholesterol, total cholesterol, and triglyceride levels. Moreover, the reduction rate was greater in patients with DM or MetS.

AB - Aim: We aimed to compare the effects of fixed-dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a subgroup analysis of patients with diabetes mellitus (DM) or metabolic syndrome (MetS). Method: This multicenter eight-week randomized double-blind phase III study evaluated the safety and efficacy of fixed-dose combinations of ezetimibe 10 mg plus rosuvastatin, compared with rosuvastatin alone in patients with primary hypercholesterolemia. Four hundred and seven patients with primary hypercholesterolemia who required lipid-lowering treatment according to the ATP III guideline were randomized to one of the following six treatments for 8 weeks: fixed-dose combinations with ezetimibe 10 mg daily plus rosuvastatin (5, 10, or 20 mg daily) or rosuvastatin alone (5, 10, or 20 mg daily). Results: Fixed-dose combination of ezetimibe plus rosuvastatin significantly reduced LDL cholesterol, total cholesterol, and triglyceride levels compared with rosuvastatin alone. Depending on the rosuvastatin dose, these fixed-dose combinations of ezetimibe plus rosuvastatin provided LDL cholesterol, total cholesterol, and triglyceride reductions of 56%–63%, 37%–43%, and 19%–24%, respectively. Moreover, the effect of combination treatment on cholesterol levels was more pronounced in patients with DM or MetS than in non-DM or non-MetS patients, respectively, whereas the effect of rosuvastatin alone did not differ between DM vs non-DM or MetS vs non-MetS patients. Conclusion: Fixed-dose combinations of ezetimibe and rosuvastatin provided significantly superior efficacy to rosuvastatin alone in lowering LDL cholesterol, total cholesterol, and triglyceride levels. Moreover, the reduction rate was greater in patients with DM or MetS.

KW - Cholesterol

KW - Diabetes mellitus

KW - Ezetimibe

KW - Hypercholesterolemia

KW - Metabolic syndrome

KW - Rosuvastatin

UR - http://www.scopus.com/inward/record.url?scp=84991094126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991094126&partnerID=8YFLogxK

U2 - 10.1111/1755-5922.12213

DO - 10.1111/1755-5922.12213

M3 - Article

C2 - 27506635

AN - SCOPUS:84991094126

VL - 34

SP - 371

EP - 382

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 5

ER -